Biomarin Pharmaceutical Inc BMRN:NASDAQ

Last Price$75.08Cboe Real-Time Last Sale as of 9:58AM ET 10/18/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.81(1.07%)
Bid (Size)$74.90 (250)
Ask (Size)$75.34 (187)
Day Low / High$74.84 - 75.81
Volume104.5 K

Sector Update: Health Care Stocks Falling This Afternoon

3:54PM ET 9/07/2021 MT Newswires
Health care stocks traded above their earlier lows this afternoon, with the NYSE Health Care Index falling 0.7% while the SPDR Health Care Select Sector ETF (XLV) was down 0.6%.

The Nasdaq Biotechnology index was dropping 0.2%.

In company news, BioMarin Pharmaceutical (BMRN) dropped 8.5% after saying the US Food and Drug Administration placed a clinical hold on phase I/II testing of its BMN 307 gene therapy candidate in adults with phenylketonuria after pre-clinical data showed mice treated with the highest dose of BMN 307 had liver tumors after 52 weeks.

Forward Pharma (FWP) shares dropped nearly 19% after the Danish drug maker said the European Patent Office dismissed its appeal of the agency's decision to revoke the EP2801355 patent for its multiple sclerosis medication.

CorMedix Inc. (CRMD) tumbled over 24% after the biopharmaceuticals company said facility deficiencies at the contract manufacturer for its DefenCath antibacterial and antifungal investigational medication will indefinitely delay the resubmission of the new drug application for the prospective treatment for catheter-related bloodstream infections. The facility issues are unrelated to DefenCath, CorMedix said, adding it will provide an update when more information become available.

To the upside, RenovoRX (RNXT) raced more than 21% higher after the company Tuesday secured 510(k) clearance from the US Food and Drug Administration for its RenovoCath dual-balloon infusion catheter system delivering the company's RenovoGem chemotherapy directly to tumors via the patient's arteries.